Divalproex Sodium Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Divalproex Sodium Market is segmented by Product Type (Tablet, Capsules, and Syrup), Application (Epilepsy, Manic-Depressive Illness, and Other Applications), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Report Offers Values (in USD million) for the Above Segments.

Market Snapshot

Study Period: 2018-2026
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 6.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The divalproex sodium market is projected to register a CAGR of 6.2% during the forecast period.

The COVID-19 pandemic has been continuing to transform the growth of various markets, and the immediate impact of the outbreak is varied. While a few industries registered a drop in demand, numerous other markets may continue to remain unscathed and show promising growth opportunities. Initially, the outbreak of COVID-19 showed an impact on the divalproex sodium market by directly affecting its production, creating supply chain disruptions, and creating a financial impact on firms due to social distancing and lockdown measures taken by governments. However, the demand for divalproex sodium is expected to rise at a considerable pace in the coming years.

Moreover, the major factors responsible for the growth of the divalproex sodium market include the growing incidence rates of bipolar disorders, rising patient pool with epilepsy and migraine headaches, increasing government initiatives, and rising research and development to introduce new products.

The increasing prevalence of bipolar disorders worldwide is propelling market growth. According to a study conducted by the National Alliance on Mental Illness in 2017, the average age-of-onset of bipolar disorder is about 25 years, but it can occur in the teens, or more uncommonly, in childhood. The condition affects men and women equally, with about 2.8% of the US population diagnosed with bipolar disorder and nearly 83% of cases classified as severe.

Moreover, globally, the expanding patient pool affected with epilepsy and migraine headaches is also expected to significantly boost the demand in the divalproex sodium market. For instance, according to the World Health Organization's Key Facts - 2018, around 50 million people were globally affected by epilepsy, making it one of the most common neurological diseases, and around 80% of the people with epilepsy live in low- and middle-income countries.

According to the National Hospital Ambulatory Medical Care Survey, the National Ambulatory Medical Care Survey, and the National Health Interview Survey, in 2018, the age-adjusted prevalence of migraine was 15.9% across all adults in the United States. The sex ratio also remains stable, affecting 21% of women and 10.7% of men. Furthermore, the increasing awareness regarding diseases and various government initiatives to prevent migraines are expected to propel the growth of the divalproex sodium market.

However, stringent regulations and increasing neurobehavioral adverse effects, congenital disabilities, and suicidal tendencies due to the usage of divalproex sodium are expected to restrain the growth of the divalproex sodium market.

Scope of the Report

As per the scope of the report, divalproex sodium is an anti-epileptic drug that is prescribed to patients with bipolar disorder, migraine headaches, and certain types of seizures. This drug is known for its anticonvulsant property for the treatment of epilepsy.

The divalproex sodium market is segmented by product type (tablet, capsules, and syrup), application (epilepsy, manic-depressive illness, and other applications), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers values (in USD million) for the above segments.

Epilepsy and Migraine Headaches
Manic-Depressive Illness
Other Applications
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Epilepsy and Migraine Headaches Segment is Expected to Account for the Largest Market Share During the Forecast Period

Epilepsy is one of the most common nervous system disorders that cause seizures. When there is an enduring predisposition to seizures, it is called epilepsy. It can affect people of any age, ranging from children to adults, across all races and backgrounds. For instance, seizures and epilepsy are some of the challenging health issues faced by many children. An epileptic seizure is said to be an abnormal electrical activity in one's brain. It is a state of neurological activity that feels like a shock wave traveling through the brain, and the recurrence of these repetitive unprovoked seizures is called epilepsy.

Migraine is a medical condition that involves severe, recurring headaches and other symptoms. Before the headache, there may be sensory changes that are known as an aura. As per an article published by the American Academy of Family Physicians (AAFP) in 2018, more than 15% of adults in the United States had experienced a migraine episode or a severe headache within the given three months. According to the Migraine Research Foundation, 12% of the population, including children, suffers from migraines and around 18% of American women, 6% of men, and 10% of children experience migraines.

A rise in the number of people affected by epilepsy and migraine headaches is projected to result in the largest market share for the segment during the forecast period. Epilepsy is triggered by certain health conditions, like brain tumors, strokes, brain infections, neurological defects, lack of oxygen to the brain, and hyperpyrexia. Traumatic head and brain injuries, specific genetic conditions, smoking, and alcohol consumption can also lead to epilepsy. However, migraine is triggered by hormonal changes, emotional triggers, such as stress, depression, and anxiety, dietary factors, like alcohol, caffeine, and medications, and environmental factors.

In the present scenario, people's lifestyles have induced anxiety and stress in their daily lives. Thus, the patient pool affected by epilepsy and migraine headaches is expected to increase during the forecast period and contribute as a driving factor for the growth of the divalproex sodium market.


North America is Expected to Hold a Significant Market Share During the Forecast Period

In North America, the US divalproex sodium market holds the major share. Increased government initiatives and rising research and development activities aimed at launching new products are expected to aid the growth of the divalproex sodium market in the region. According to the Centers for Disease Control and Prevention, approximately 3 million adults and 470,000 children in the United States have epilepsy. According to a survey conducted by Therapeutic Advances in Psychopharmacology (2018) across 11 countries, the lifetime prevalence of bipolar disorder was observed to be 2.4%; out of which the United States accounted for 1%, which was found to be higher than those in other countries considered in the survey.

Furthermore, in 2019, Lupin received the US FDA's approval for its divalproex sodium extended-release tablets, USP 250 mg and 500 mg, to commercialize the generic equivalent of Depakote extended-release tablets (250 mg and 500 mg) offered by AbbVie. Such advancements are expected to drive the market's growth over the forecast period.


Competitive Landscape

The divalproex sodium market is consolidated and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies that are currently dominating the market are AbbVie Inc., Zydus Cadila, Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd, Lupin Pharmaceuticals Inc., Orchid Pharma Ltd, Sun Pharmaceuticals Industries Ltd, Teva Pharmaceutical Industries Ltd, and Abbott Laboratories.

Recent Developments

In September 2020, Lupin launched the divalproex sodium extended-release tablets, USP 250 mg and 500 mg, after receiving approval from the US FDA (Food and Drug Administration).

In November 2020, Aurobindo Pharma announced the completion of the acquisition of MViyeS Pharma Ventures. Aurobindo Pharma is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs).

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Incidence Rates of Bipolar Disorders

      2. 4.2.2 Expanding Patient Pool with Epilepsy and Migraine Headaches

      3. 4.2.3 Increasing Government Initiatives and Rising Research and Development Activities to Introduce New Products

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulations

      2. 4.3.2 Increasing Neurobehavioral Adverse Effects, Birth Defects, and Suicidal Tendencies due to Divalproex Sodium Usage

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 Type

      1. 5.1.1 Tablet

      2. 5.1.2 Capsule

      3. 5.1.3 Syrup

    2. 5.2 Application

      1. 5.2.1 Epilepsy and Migraine Headaches

      2. 5.2.2 Manic-Depressive Illness

      3. 5.2.3 Other Applications

    3. 5.3 Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Online Pharmacies

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie Inc.

      2. 6.1.2 Zydus Cadila

      3. 6.1.3 Aurobindo Pharma

      4. 6.1.4 Dr. Reddy's Laboratories Ltd

      5. 6.1.5 Lupin Pharmaceuticals Inc.

      6. 6.1.6 Orchid Pharma Ltd

      7. 6.1.7 Sun Pharmaceuticals Industries Ltd

      8. 6.1.8 Teva Pharmaceuticals Industries Ltd

      9. 6.1.9 Abbott Laboratories

    2. *List Not Exhaustive

**Competitive Landscape Covers Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Divalproex Sodium Market market is studied from 2018 - 2026.

The Global Divalproex Sodium Market is growing at a CAGR of 6.2% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

AbbVie Inc., Lupin Pharmaceuticals, Inc., Dr. Reddy's Laboratories Ltd., Zydus Cadila, Aurobindo Pharma are the major companies operating in Global Divalproex Sodium Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!